1-800 Pharmacy, Inc. Participates In ERSP Forum

New York, NY – October 7, 2005 – The Electronic Retailing Self-Regulation Program (ERSP) announced that 1-800 Pharmacy, Inc. (1-800 Pharmacy), marketers of the OHT Peptide-3 Anti- Aging Formula , have a basis to make general technological claims, but have been asked to modify certain technological, establishment, and comparative claims made in their online advertising. The marketer’s advertising was reviewed pursuant to an anonymous competitive challenge.

ERSP, the electronic direct-response industry’s self-regulatory forum supervised by the National Advertising Review Council (NARC), asked 1-800 Pharmacy to provide substantiation for core claims in the advertising for its OHT Peptide-3 Anti-Aging Formula , including:

“… repair[s] stretch marks”
Acetyl Hexypeptide-3 is “clinically proven” to smooth wrinkles by relaxing tense facial muscles.
“Experience OHT Peptide-3’s Safe, Botox®-like Effects”

ERSP does not object to the dissemination of general ingredient information regarding OHT Peptide-3 provided by 1- 800 Pharmacy on its website, but concluded that the claims stating specific results needed modification. ERSP also determined that it would be reasonable for consumers to interpret performance claims, specifically the clinically proven claims, as meaning that the ingredients were tested at the same level or concentration as they are contained in the product which was not the case based on the marketer’s referenced studies. Finally, ERSP determined that the claim “Experience OHT Peptide-3’s Safe, Botox- like Effects” was presented in such a context (i.e. “Learn about …”) that did not rise to the level of an express comparison, however, ERSP recommended that the marketer modify the claim stating that “OHT Peptide-3 surpasses the leader with the next generation ingredients.”

In response to the ERSP decision, 1-800 Pharmacy represented that it “…accepts ERSP’s analysis and has modified, and will continue to modify, the language of its site, packaging, and/or advertising as suggested.”

 

Subscribe to the Ad Law Insights or Privacy Initiatives newsletters for an exclusive monthly analysis and insider perspectives on the latest trends and case decisions in advertising law and data privacy.

 

 

 

 

Latest Decisions

Decision

National Advertising Division Recommends Oral Essentials Discontinue "Certified Non-Toxic" Claim for its Lumineux Mouthwash

New York, NY – December 30, 2024 – In a Fast-Track SWIFT challenge brought by GuruNanda, the National Advertising Division recommended that Oral Essentials discontinue its claim that Lumineux mouthwash products are “Certified Non-Toxic.” 

Read the Decision Summary
Decision

NARB Recommends T-Mobile Discontinue or Modify Commercial to Better Disclose Conditions of Free iPhone Offer, 20% Savings Claim

New York, NY – December 30, 2024 – A panel of the National Advertising Review Board (NARB) recommended that T-Mobile discontinue or modify its commercial to better disclose the material conditions of its free iPhone 16 Pro offer and its 20% rate plan savings claim compared to AT&T and Verizon. 

Read the Decision Summary
Decision

Direct Selling Self-Regulatory Council Recommends Valentus Discontinue Earnings and Product Performance Claims

McLean, VA – December 23, 2024 – The Direct Selling Self-Regulatory Council (DSSRC) recommended Valentus, a direct selling company that sells nutritional and lifestyle products, discontinue earnings and health-related product performance claims made on social media and on the Valentus website.

Read the Decision Summary
Decision

Direct Selling Self-Regulatory Council Refers Olive Tree Earnings Claims to the FTC and California AG for Possible Enforcement Action

McLean, VA – December 20, 2024 – The Direct Selling Self-Regulatory Council (DSSRC) referred Olive Tree to the Federal Trade Commission (FTC) and California Attorney General's Office for possible enforcement action after Olive Tree failed to respond to a DSSRC inquiry into earnings claims.  

Read the Decision Summary